CY1106643T1 - Αναστολεις συνθεσης βλεννινης - Google Patents

Αναστολεις συνθεσης βλεννινης

Info

Publication number
CY1106643T1
CY1106643T1 CY20071100747T CY071100747T CY1106643T1 CY 1106643 T1 CY1106643 T1 CY 1106643T1 CY 20071100747 T CY20071100747 T CY 20071100747T CY 071100747 T CY071100747 T CY 071100747T CY 1106643 T1 CY1106643 T1 CY 1106643T1
Authority
CY
Cyprus
Prior art keywords
mucine
synthesis inhibitors
diseases
chronic
mucus
Prior art date
Application number
CY20071100747T
Other languages
Greek (el)
English (en)
Inventor
Yuhong Zhou
Roy C. Levitt
Nicholas C. Nicolaides
Steve Jones
Mike Mclane
Original Assignee
Genaera Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corporation filed Critical Genaera Corporation
Publication of CY1106643T1 publication Critical patent/CY1106643T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CY20071100747T 2000-01-31 2007-06-05 Αναστολεις συνθεσης βλεννινης CY1106643T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17912700P 2000-01-31 2000-01-31
US19311100P 2000-03-30 2000-03-30
US23078300P 2000-09-07 2000-09-07
US24213400P 2000-10-23 2000-10-23
US25205200P 2000-11-20 2000-11-20
PCT/US2001/003078 WO2001054685A1 (en) 2000-01-31 2001-01-31 Mucin synthesis inhibitors

Publications (1)

Publication Number Publication Date
CY1106643T1 true CY1106643T1 (el) 2012-01-25

Family

ID=27539006

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100747T CY1106643T1 (el) 2000-01-31 2007-06-05 Αναστολεις συνθεσης βλεννινης

Country Status (13)

Country Link
US (2) US6737427B2 (https=)
EP (1) EP1255544B1 (https=)
JP (1) JP2004507444A (https=)
AR (1) AR042578A1 (https=)
AT (1) ATE355836T1 (https=)
AU (2) AU2001234671B2 (https=)
CA (1) CA2398642A1 (https=)
CY (1) CY1106643T1 (https=)
DE (1) DE60127098T2 (https=)
DK (1) DK1255544T3 (https=)
ES (1) ES2282235T3 (https=)
PT (1) PT1255544E (https=)
WO (1) WO2001054685A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355836T1 (de) * 2000-01-31 2007-03-15 Genaera Corp Inhibitoren der mucin-synthese
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
US7345051B2 (en) * 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US8474460B2 (en) 2000-03-04 2013-07-02 Pulmonx Corporation Implanted bronchial isolation devices and methods
US6679264B1 (en) 2000-03-04 2004-01-20 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US6904909B2 (en) 2000-03-04 2005-06-14 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US20030059434A1 (en) * 2000-08-09 2003-03-27 Andrew Grupe Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions
US7011094B2 (en) 2001-03-02 2006-03-14 Emphasys Medical, Inc. Bronchial flow control devices and methods of use
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
CA2458595C (en) 2001-10-11 2007-12-04 Peter M. Wilson Bronchial flow control devices and methods of use
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
US6929637B2 (en) 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
US7412977B2 (en) 2002-03-08 2008-08-19 Emphasys Medical, Inc. Methods and devices for inducing collapse in lung regions fed by collateral pathways
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US20040059263A1 (en) 2002-09-24 2004-03-25 Spiration, Inc. Device and method for measuring the diameter of an air passageway
CA2487405A1 (en) 2002-07-26 2004-02-05 Emphasys Medical, Inc. Bronchial flow control devices with membrane seal
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7100616B2 (en) 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
MXPA05012728A (es) 2003-05-28 2006-02-13 Wyeth Corp Clca-1 soluble y antagonistas para el clca-1.
AU2004249775A1 (en) * 2003-06-19 2004-12-29 Genaera Corporation Mucin synthesis inhibitors
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
JP2008507368A (ja) * 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
US9211181B2 (en) 2004-11-19 2015-12-15 Pulmonx Corporation Implant loading device and system
US7771472B2 (en) 2004-11-19 2010-08-10 Pulmonx Corporation Bronchial flow control devices and methods of use
EP1827479A1 (en) * 2004-12-09 2007-09-05 Ingenium Pharmaceuticals AG Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion
WO2006075172A2 (en) * 2005-01-13 2006-07-20 University Of Dundee Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
US8876791B2 (en) 2005-02-25 2014-11-04 Pulmonx Corporation Collateral pathway treatment using agent entrained by aspiration flow current
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
JP5570993B2 (ja) 2007-10-12 2014-08-13 スピレーション インコーポレイテッド 弁装填具の方法、システム、および装置
GB0905954D0 (en) * 2009-04-06 2009-05-20 E Therapeutics Plc Treatment of exacerbations of asthma
US9782454B2 (en) * 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012134965A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2015182565A1 (ja) * 2014-05-27 2015-12-03 リンク・ジェノミクス株式会社 肺疾患治療剤
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168313A (en) 1978-02-21 1979-09-18 Sebastian Bago Phthalidyl 2-(3'-trifluoromethyl-anilino)-pyridine-3-carboxylate and its salts
US4515980A (en) * 1983-07-11 1985-05-07 Sterling Drug Inc. Substituted aminobenzoates, their preparation and use
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DE3682136D1 (de) * 1985-07-31 1991-11-28 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DE3608726A1 (de) * 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
GB9200114D0 (en) 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
WO1996039419A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Colon specific genes and proteins
EP0839031A1 (de) * 1995-07-20 1998-05-06 JUERGENS, Uwe R. Verwendung eines nicht-steroidalen antiphlogistikums zur topischen und systemischen behandlung der akuten und chronischen polypoiden rhinosinusitis
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
SI0964865T1 (en) * 1997-01-08 2003-08-31 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
BR9810385A (pt) * 1997-07-01 2000-09-05 Warner Lambert Co Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
US6136539A (en) * 1998-02-11 2000-10-24 The Regents Of The University Of California Compositions and methods for the inhibition of MUC-5 mucin gene expression
US6576434B1 (en) 1998-03-03 2003-06-10 Genaera Corporation Methods for identification of agents which modulate chloride channel activity
EP1140062B1 (en) * 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
DE69926914T2 (de) * 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7965000A (en) * 1999-09-27 2001-04-30 Jun-Suk Oh Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same
ATE355836T1 (de) 2000-01-31 2007-03-15 Genaera Corp Inhibitoren der mucin-synthese
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
DE60127098T2 (de) 2007-11-29
PT1255544E (pt) 2007-06-15
EP1255544B1 (en) 2007-03-07
US20040254096A1 (en) 2004-12-16
US6737427B2 (en) 2004-05-18
EP1255544A1 (en) 2002-11-13
US20010041685A1 (en) 2001-11-15
AU3467101A (en) 2001-08-07
CA2398642A1 (en) 2001-08-02
DK1255544T3 (da) 2007-09-17
AU2001234671B2 (en) 2006-05-18
DE60127098D1 (de) 2007-04-19
ATE355836T1 (de) 2007-03-15
EP1255544A4 (en) 2005-02-02
ES2282235T3 (es) 2007-10-16
US7504409B2 (en) 2009-03-17
WO2001054685A1 (en) 2001-08-02
AR042578A1 (es) 2005-06-29
JP2004507444A (ja) 2004-03-11

Similar Documents

Publication Publication Date Title
CY1106643T1 (el) Αναστολεις συνθεσης βλεννινης
CY1122346T1 (el) Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
NO20061254L (no) Farmasoytiske blandinger
CY1108937T1 (el) Χρηση της κινασης πρωτεϊνης ν-β
WO2004043392A3 (en) Mucin synthesis inhibitors
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
EA200200739A1 (ru) Пиримидинкарбоксамиды, используемые в качестве ингибиторов изосимов pde4
CY1109712T1 (el) Φαρμακευτικες συνθεσεις με βαση τιοτροπιο, κικλεσονιδη και ενα βητα μιμητικο για τη θεραπεια φλεγμονωδων και/ή αποφρακτικων παθησεων των αναπνευστικων οδων
CR7025A (es) Derivados biarilicos de nicotinamida de utilidad como inhibidores de isozimas pde4
JO3150B1 (ar) مشتقات بيريدين و بيرازين لعلاج مرض cf
CY1109194T1 (el) Παραγωγα ν-υδροξυαμιδιου και η χρηση του
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
PA8537901A1 (es) Derivados de eteres utiles como agentes inhibidores de las isozimas pde4
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
ATE534630T1 (de) Sulfonamidderivate und deren verwendung zur modulation von metalloproteinasen
WO2004113286A3 (en) Mucin synthesis inhibitors
EA200100515A2 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
BG106748A (en) Method and compositions for treating pulmonary diseases
SE9900834D0 (sv) Novel combination
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
WO2003011294A3 (en) Mucin synthesis inhibitors
NO965469D0 (no) Substituerte alkyldiaminderivater og deres anvendelse som tachykininantagonister
BRPI0516383A (pt) derivados cìclicos de sulfonil amino e o uso dos mesmos
NO20074458L (no) N-hydroksamidderivater og anvendelse derav